In the Toprol case, Faruqi & Faruqi, LLP represents a pharmaceutical wholesaler and a class of direct purchasers of AstraZeneca’s branded drug Toprol XL (extended-release metoprolol succinate). The case alleges that AstraZeneca fraudulently procured two patents and filed multiple baseless patent infringement lawsuits using those patents, solely in an effort to delay less-expensive generic competition, a violation of § 2 of the Sherman Act. A $20 million settlement in the case has been approved by the court, and final judgment has been entered.
Faruqi & Faruqi, LLP
101 Greenwood Avenue Suite 600
Jenkintown, PA 19046
Tel: (215) 277-5770
If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.